July 27, 2023

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

Symbol: LALPATHLAB

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Scrip Code: 539524

Sub: **Press Release on Un-Audited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2023**

Dear Sir/ Madam,

Please find enclosed herewith the Press Release on the Un-Audited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2023.

We request you to please take the same on record.

Thanking You,
Yours Faithfully,

For Dr. Lal PathLabs Limited

Vinay Gujral
Company Secretary & Compliance Officer

Encl.: As above

Dr Lal PathLabs Limited records revenue of Rs 541 Cr in Q1 FY 2023-24

New Delhi, India, July 27, 2023 – Dr Lal PathLabs Limited (referred to as the "Company"; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended June 30, 2023.

Consolidated Performance Highlights: Q1 FY 2023-24 vs Q1 FY 2022-23

- Non-Covid Revenue increased by 9.7% in Q1 FY24

- Normalised EBITDA margin (after adjustment for stock based compensation & CSR) for Q1 FY24 is 28.4%

- PAT margin for Q1 FY24 is 15.4%

Financial Overview (Consolidated) in Rs Cr

Particulars	Q1		
	FY24	**FY23**	*Gr %*
Revenue	**541**	**503**	*7.6%*
Non Covid	*528*	*482*	*9.7%*
Covid & Allied	*13*	*21*	*-39.9%*
Operating Expenditure	**387**	**377**	*2.6%*
Normalised EBITDA	**154**	**125**	*22.7%*
Margins	*28.4%*	*25.0%*	
RSU & CSR cost	8	8	
EBITDA	**146**	**118**	*24.4%*
Margins	*27.0%*	*23.4%*	
Other Income	14	8	
Depreciation Cost	35	36	
EBIT	**126**	**90**	*39.6%*
Finance Cost	8	8	
PBT	**117**	**81**	*44.3%*
Margins	*21.7%*	*16.2%*	
PAT	**84**	**58**	*43.6%*
Margins	*15.4%*	*11.6%*	
EPS	**9.9**	**7.0**	*42.7%*

About Dr Lal PathLabs Limited

Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2023 the company has 277 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 5,102 Patient Service Centers (PSCs) and 10,938 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Goel
Group Chief Financial Officer
Dr Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Rakshit Tewari/ Kritika Khatwani
Adfactors PR

+91 9935551036/+91 8604801332
rakshit.tewari@adfactorspr.com
kritika.khatwani@adfactorspr.com

For further information on Dr Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.